Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Arrowstreet Capital Limited Partnership lowered its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 5.4% during the second quarter, Holdings Channel reports. The institutional investor owned 1,697,225 shares of the company’s stock after selling 96,228 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Amneal Pharmaceuticals were worth $13,731,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMRX. Vanguard Group Inc. increased its holdings in shares of Amneal Pharmaceuticals by 6.2% during the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after acquiring an additional 920,758 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Amneal Pharmaceuticals by 14.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,767,594 shares of the company’s stock worth $14,812,000 after purchasing an additional 227,660 shares during the last quarter. Deutsche Bank AG raised its stake in Amneal Pharmaceuticals by 128.3% in the 1st quarter. Deutsche Bank AG now owns 305,621 shares of the company’s stock worth $2,561,000 after acquiring an additional 171,735 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Amneal Pharmaceuticals during the first quarter worth about $31,000. Finally, Invesco Ltd. boosted its position in Amneal Pharmaceuticals by 19.2% in the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company’s stock valued at $19,045,000 after buying an additional 365,467 shares during the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $11.87 on Tuesday. The firm has a fifty day moving average of $11.08 and a 200 day moving average of $9.47. The firm has a market cap of $3.73 billion, a PE ratio of 593.80 and a beta of 1.36. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $12.68.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating and set a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. JPMorgan Chase & Co. upped their price target on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Barclays assumed coverage on Amneal Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $15.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $13.50.

Insider Activity

In other news, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the transaction, the director owned 291,029 shares in the company, valued at $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the completion of the sale, the executive vice president directly owned 146,403 shares in the company, valued at $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 231,856 shares of company stock worth $2,743,724. 17.45% of the stock is currently owned by insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.